Bariatric surgery, the most effective current treatment for patients with obesity, can significantly reduce many adult patients’ risks of developing and dying from obesity-related cancers, a new study led by Cleveland Clinic researchers has found.
T-DM1/Neratinib Combination is Safe and Effective in Patients With Metastatic HER2-Positive Breast Cancer
A dual blockade approach combining the antibody drug conjugate ado-trastuzumab emtansine with the tyrosine kinase inhibitor neratinib shows encouraging results for patients with HER2-positive metastatic breast cancer, according to a recent clinical trial that also identified a clue to the mechanism behind anti-HER2 therapy resistance in some patients.
Shortening the Wait for Cancer Treatment
How did Cleveland Clinic Cancer Center reduce waiting times for cancer treatment by 33% in four years? As a new column in the ASCO Post explains, it started with a change in institutional mindset and a commitment to treat patients like family members.
New Approach May Help Predict HER2+ Tumor Response to Treatment
Researchers have identified quantitative features extracted from MRI images of HER2-positive breast tumors and the tumor environment that may provide cues to patients’ likelihood of response to targeted chemotherapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Why Ears Are More Important than Stethoscopes
Scans, stats and blood work provide only a fraction of the information needed to treat cancer patients, says Jame Abraham, MD, Cleveland Clinic’s Director of Breast Oncology. Read his editorial in U.S. News & World Report.
T-DM1 + Neratinib’s Safety and Efficacy in Women with Metastatic HER2+ Breast Cancer
Results of a multi-institutional phase 1b clinical trial show women with metastatic HER2+ breast cancer respond well to the combina-tion of trastuzumab emtansine and neratinib.
Is Work-Life Balance Possible in Medicine?
Only if you love what you do, says Jame Abraham, MD, Director of the Breast Oncology Program. A healthy work environment is equally as crucial.
Neratinib FDA Approval for Extended Adjuvant Therapy a Win for HER2+ Patients
This most recent FDA approval is a testament of neratinib’s efficacy in improving disease-free survival in high risk HER2-positive patients after one year of trastuzumab.
Promising New Combination Therapy for Advanced, HER2+ Breast Cancer Shown Safe and Effective
Neratinib and T-DM1 combination therapy has been shown safe and effective for women with advanced, HER2-poitive breast cancer. A phase 1B dose escalation trial shows a 56 percent response rate, with 19 percent showing complete response for up to 18 months.
Promise of PARP Inhibitors for BRCA1/BRCA2 Cancers
Two new clinical trials are evaluating olaparib therapy for women with metastatic breast cancer and stage II/III breast cancers marked by BRCA1/BRCA2 mutations and other DNA repair pathway defects.